Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
Open Access
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 14 (8) , 1021-1027
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patientsMedecine Et Maladies Infectieuses, 2020
- Risk factors for severity and mortality in adult COVID-19 inpatients in WuhanJournal of Allergy and Clinical Immunology, 2020
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Postmortem Examination of Patients With COVID-19JAMA, 2020
- Supportive Treatment with Tocilizumab for COVID-19: A Systematic ReviewJournal of Clinical Virology, 2020
- Covid-19 in Critically Ill Patients in the Seattle Region — Case SeriesNew England Journal of Medicine, 2020
- Tocilizumab for the treatment of severe coronavirus disease 2019Journal of Medical Virology, 2020
- COVID-19 and the HeartCirculation Research, 2020
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposalThe Journal of Heart and Lung Transplantation, 2020
- Clinical and immunological features of severe and moderate coronavirus disease 2019Journal of Clinical Investigation, 2020